Remove Bioinformatics Remove Information Remove Research
article thumbnail

Why Mallory Freeberg is creating a perturbation catalogue

The Open Targets Blog

Many research groups have generated perturbation-type experimental data, but this data is currently varied and disparate. The Perturbation Catalogue is a great opportunity to consider how we bring this data together to enable researchers to make the most of it. Perturbation Catalogue home page How will researchers use your data?

article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. At the heart of any research is the scientific question. The next critical step is the sanity check phase, where the integrity of the dataset is assessed.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What single cells are revealing about brain disorders

Drug Target Review

At the centre of this shift is 10x Genomics – a company building tools that enable researchers to study individual cells and their gene activity, both in isolation and in their original spatial context. I got my eyes opened to molecular biology, bioinformatics, computational biology and these emerging fields at the time.”

article thumbnail

Genomic score predicts patients' progression to multiple myeloma

Broad Institute

In the future, the MM-like score could be used in clinical practice to inform decisions about early intervention. This study brings us closer to more personalized care for patients with a precursor stage of cancer and could better inform early intervention strategies in the future. The study was published in Nature Genetics.

DNA 52
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Multimodality however can detect and connect trends (and in future generate content) across different modalities and therefore allows for better interpretability, which builds trust between regulators, researchers and industry stakeholders. This approach limits the transformative potential of the technology.

Drugs 65
article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 2

Drug Target Review

In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research.

Drugs 73
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

There will also be a poster award for early-career professionals recognising the research that the next generation of scientists bring to drug discovery. There, he worked with the GENCODE consortium to establish foundational lncRNA gene annotations, which are considered a standard reference in the field.

RNA 59